Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Emmaus Life Sciences, Inc.

https://www.emmausmedical.com/

Latest From Emmaus Life Sciences, Inc.

Asia Deal Watch: Emmaus, Kainos Pursue R&D In Cancers With Limited Therapy Options

Plus deals involving WuXi AppTec/OXGENE, Oscotec/Beatica, ReViral/LianBio, Wugen/HCW Biologics, Starton/Haisco, Shanghai Junshi/AstraZeneca, HitGen/Uppthera, Bridge/LegoChem, Macrogen/Lifex, BeiGene/Boston Immune

Deals Business Strategies

ICER Will Assess Real World Evidence On Accelerated Approvals After Two Years

Process will incorporate real world evidence into future cost effectiveness updates of already reviewed drugs to supplement the information available prior to launch.

Health Technology Assessment Pricing Strategies

Sickle Cell Disease Market Snapshot: "The Time Has Come"

Three new drugs for sickle cell disease could be on the market in the US next year, representing a groundswell of advancement for the devastating blood disorder that has had limited options.

Market Snapshot Blood & Coagulation Disorders

Emmaus: ‘We Might Stand A Better Chance In Europe Without The EMA’

Emmaus Life Sciences is dusting itself off following the rejection by the European Medicines Agency of the company’s sickle cell disease drug, Xyndari. The company tells the Pink Sheet that it might have better luck in Europe on a country-by-country basis in member states where experts have shown support for its product and where there are many patients with the condition. Not surprisingly, the EMA has defended the system it follows.

Drug Review Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • AFH Acquisition IV, Inc.
    • Emmaus Holdings, Inc.
    • Emmaus Medical, Inc.
    • EMI, Inc.
    • EMI Holding, Inc.
    • MYnd Analytics, Inc.
UsernamePublicRestriction

Register